It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...
T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...
The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...
The TERZO study evaluates Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma, lacking a standard treatment. The trial compares Copiktra with Gemzar or Bendeka, focusing on ...
Global trends in prevalence and incidence of pancreatic cancer among adults aged 70 and older: A comprehensive analysis of the Global Burden of Disease study (1990–2021). This is an ASCO Meeting ...
Adult T-cell leukemia–lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: ...
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma. Treatment with the CAR T-cell therapy Yescarta ...
Wistar Institute scientists have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results